Odongo Charles O, Bisaso Kuteesa R, Kitutu Freddy, Obua Celestino, Byamugisha Josaphat
Department of Pharmacology and Therapeutics, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda.
Department of Pharmacology and Therapeutics, Faculty of Medicine, Gulu University, Gulu, Uganda.
Malar J. 2015 May 3;14:189. doi: 10.1186/s12936-015-0702-7.
In Uganda, treatment of clinical malaria and intermittent preventive treatment with sulphadoxine-pyrimethamine (SP) are common during pregnancy. As a result, both formal and informal reports from antenatal sources suggest possible misuse of SP for malaria treatment among pregnant women. The objective of this study was to investigate anti-malarial drug use patterns among women who had recently suffered malaria illness before and during pregnancy.
A cross-sectional study in which a structured questionnaire (interviewer-administered) was used to collect data from pregnant women attending an urban antenatal clinic. Details of medicines used to treat malaria episodes suffered before and during pregnancy were captured. A first order Markov probability model was used to estimate probabilities of transitioning between treatment choices made before and during pregnancy. Logistic regression was used to explore whether demographic and obstetric characteristics were associated with transition patterns.
Seven hundred women were interviewed among whom 428 had suffered malaria in both instances. Three hundred thirty of these could recall the medicines used in both instances. Women who used ACT/QNN (correct choice) before pregnancy had higher probabilities of transitioning to SP than staying on ACT/QNN during pregnancy (0.463 versus 0.451). Access of medicines from private outlets (clinics and pharmacies) were more than nine times predictive of receiving correct medicines (p=0.035 and p=0.039 respectively). Access of medicines from clinics was 5.9 times protective against receiving SP for malaria treatment (p=0.033). Among those who used SP before pregnancy, there was a 0.75 probability of staying on it during pregnancy. None of the factors explored could explain this observation.
Use of SP for malaria treatment is common during pregnancy. This may be contributing to adverse pregnancy outcomes. Antenatal care providers should endeavour to emphasize the distinction between treatment and prevention of malaria during pregnancy.
在乌干达,孕期治疗临床疟疾和使用磺胺多辛-乙胺嘧啶(SP)进行间歇性预防治疗很常见。因此,来自产前资料的正式和非正式报告均表明,孕妇中可能存在将SP误用为疟疾治疗药物的情况。本研究的目的是调查近期在孕前和孕期患疟疾的妇女的抗疟药物使用模式。
采用横断面研究,使用结构化问卷(由访谈员进行询问)从一家城市产前诊所的孕妇中收集数据。记录用于治疗孕前和孕期疟疾发作的药物细节。使用一阶马尔可夫概率模型估计孕前和孕期治疗选择之间转换的概率。采用逻辑回归分析探讨人口统计学和产科特征是否与转换模式相关。
共访谈了700名妇女,其中428名在两个阶段都患过疟疾。其中330名能够回忆起两个阶段使用的药物。孕前使用青蒿琥酯/阿莫地喹(正确选择)的妇女在孕期转为使用SP的概率高于继续使用青蒿琥酯/阿莫地喹的概率(分别为0.463和0.451)。从私人机构(诊所和药店)获取药物的情况预测接受正确药物治疗的可能性高出九倍以上(分别为p = 0.035和p = 0.039)。从诊所获取药物可使接受SP治疗疟疾的可能性降低5.9倍(p = 0.033)。在孕前使用SP的妇女中,孕期继续使用的概率为0.75。所探讨的因素均无法解释这一现象。
孕期使用SP治疗疟疾很常见。这可能会导致不良妊娠结局。产前护理提供者应努力强调孕期疟疾治疗和预防的区别。